Safety, Tolerability, and Pharmacokinetics of PF‐06823859, an Anti–Interferon β Monoclonal Antibody: A Randomized, Phase I, Single‐ and Multiple‐Ascending‐Dose Study-Reference-Cited by-同舟云学术

Safety, Tolerability, and Pharmacokinetics of PF‐06823859, an Anti–Interferon β Monoclonal Antibody: A Randomized, Phase I, Single‐ and Multiple‐Ascending‐Dose Study

Published:2020-12-22 Issue:3 Volume:10 Page:307-316
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:Clinical Pharmacology in Drug Development

Author:

Neelakantan Srividya¹,Oemar Barry¹,Johnson Kristen²,Rath Natalie³,Salganik Mikhail¹,Berman Gabe⁴,Pelletier Kathleen⁵,Cox Lori³,Page Karen¹,Messing Dean¹,Tarabar Sanela⁶

Affiliation:

1. Worldwide Research and Development Pfizer Inc Cambridge Massachusetts USA

2. Center for Therapeutic Innovation Pfizer Inc New York New York USA

3. Pfizer Inc Collegeville Pennsylvania USA

4. Pfizer Inc San Diego California USA

5. Pfizer Inc Groton Connecticut USA

6. Pfizer Clinical Research Unit New Haven Connecticut USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Link